SCHEMBL3045956

SCHEMBL3045956

c1ccc(COc2ccc3c(c2)CCN(Cc2ccccc2)C3)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REV1 Q9UBZ9 1/20 0.70
HRH3 Q9Y5N1 10/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
CYP2D6 P10635 3/20 0.65
HRH1 P35367 2/20 0.65
CARM1 Q86X55 1/20 0.64
DRD4 P21917 2/20 0.58
HTR2B P41595 2/20 0.58
TMEM97 Q5BJF2 2/20 0.58
SIGMAR1 Q99720 2/20 0.58
CHRM2 P08172 1/20 0.58
HTR1A P08908 1/20 0.58
CHRM3 P20309 1/20 0.58
ADRA1D P25100 1/20 0.58
HTR2C P28335 1/20 0.58
ADRA1A P35348 1/20 0.58
ADRA1B P35368 1/20 0.58
DRD3 P35462 1/20 0.58
SLC6A3 Q01959 1/20 0.58
OPRM1 P35372 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3050358 0.88 L3MBTL1 (0.69) REV1HRH3L3MBTL1CYP2D6HRH1
SCHEMBL22755424 0.86 HRH3 (0.65) REV1HRH3L3MBTL1CYP2D6HRH1
SCHEMBL23259283 0.86 HRH3 (0.65) REV1HRH3L3MBTL1HRH1CARM1
SCHEMBL8188071 0.82 HRH3 (0.92) REV1HRH3L3MBTL1CYP2D6HRH1
SCHEMBL4917832 0.82 HRH3 (0.77) REV1HRH3L3MBTL1CYP2D6HRH1
SCHEMBL566650 0.81 CARM1 (0.58) REV1HRH3L3MBTL1CYP2D6HRH1
SCHEMBL29474881 0.81 HRH3 (0.70) REV1HRH3L3MBTL1CYP2D6HRH1
SCHEMBL3054852 0.80 CA9 (0.62) REV1L3MBTL1HRH1DRD4HTR2B
SCHEMBL5450398 0.80 HRH3 (1.00) HRH3CYP2D6HRH1CARM1DRD4
SCHEMBL4927686 0.79 HRH3 (1.00) HRH3CYP2D6HRH1CARM1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155192-B1 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LTD (GB) 2016-09-28 EP disclosed
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US disclosed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US disclosed
CN-101677993-A Compound (I) STERIX LTD 2010-03-24 CN disclosed
EP-2155192-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS Sterix Limited (GB) 2010-02-24 EP disclosed
WO-2008117061-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LIMITED (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222299-A1 COMPOUND MKI67, VHL, MYC REV1 1520/4885HRH3 2790/4885L3MBTL1 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.